Showing 51-60 of 3024 results for "".
MS Minute: Ibudilast
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-ibudilast/31622/Ibudilast is a phosphodiesterase inhibitor that has shown some benefit for progressive multiple sclerosis in a phase 2 trial.Approaches to MS Care in Later Life: Distinguishing Aging from Disease
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/approaches-to-ms-care-in-later-life/37227/Distinguishing Aging from DiseaseACTRIMS 2016 Forum Coverage: Updates in MS Therapeutics and Research
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/actrims-2016-forum-coverage-updates-in-ms-therapeutics-and-research/30481/MS Minute: Menopause and Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minutebrmenopause-and-multiple-sclerosis/32119/Multiple sclerosis and menopause have overlapping symptoms, complicating evaluation of disease progression and care of this population.MS THERAPY FOCUS SHIFTS TO ORAL COMPOUNDS
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/PN0509_news02-php/30927/Delayed MS Drugs Awaits Decision at FDA
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/delayed-ms-drugs-awaits-decision-at-fda/30657/Tysabri and MS: Putting the Odds in the Patient's Favor
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/tysabri-and-ms-putting-the-odds-in-the-patients-favor/30762/A recent analysis has created a better profile of who can receive Tysabri and when.Choosing an MS Treatment for the Individual Patient
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/choosing-an-ms-treatment-for-the-individual-patient/31983/Patient Expectations, Market Predictions Focus on Oral MS Drugs
https://practicalneurology.com/columns/practice-management/patient-expectations-market-predictions-focus-on-oral-ms-drugs/30711/As Treatment Options Expand, Researchers Continue to Explore the Basis of MS
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/as-treatment-options-expand-researchers-continue-to-explore-the-basis-of-ms/30601/New treatments have emerged and others are expected. What have changes meant for patient care?